Case Report: PD-L1-Armored CAR-T Cell Therapy for Relapsed B-ALL

A 2026 case report from figshare details a single adult patient with early-relapsed, chemorefractory B-cell acute lymphoblastic leukemia (B-ALL). The report describes a treatment regimen involving co-infusion of CD19 and PD-L1-armored CD22 CAR-T cells, followed by allogeneic hematopoietic stem cell transplantation, resulting in a 7-year sustained remission. The dataset is a 27.3 KB DOCX file authored by Huan Hua, licensed under CC-BY-4.0.

Use Cases

• Analyze long-term safety and efficacy of dual-targeted CAR-T cell therapy based on the described treatment protocol and 7-year follow-up.
• Study the bridging strategy to allogeneic hematopoietic stem cell transplantation based on the clinical workflow described in the case report.
• Investigate methods for overcoming PD-L1/PD-1 axis-mediated immunosuppression based on the description of the PD-L1-armored CAR-T cell construct.
• Review diagnostic and monitoring techniques for minimal residual disease based on the mention of 8-color multiparameter flow cytometry and next-generation sequencing.

Strengths

• Provides detailed clinical and methodological data for a single case, including specific CAR-T cell doses (5.0×10⁵ cells/kg and 3.1×10⁵ cells/kg).
• Reports a long-term clinical outcome of 7-year sustained remission, which is a notable duration for this patient population.
• Includes specific diagnostic methods such as 8-color multiparameter flow cytometry with a stated sensitivity of 0.01%.

Limitations

• The dataset is a single case report (n=1), limiting statistical power and generalizability of findings.
• Row count and column-level documentation are unknown, which may limit suitability assessment for structured analysis.
• The data is contained within a DOCX document, requiring text extraction for computational analysis.

Provenance

Source

figshare, authored by Huan Hua.

Collection Method

Retrospective clinical case report from a single center.

Time Range

Covers the treatment and follow-up period for a single patient, culminating in a 7-year remission.

Freshness

Last updated 2026-04-27 05:16:39.

Geography

Likely based in China, given the mention of the Ethics Committee of the Second Hospital of Hebei Medical University.